2月6日,《自然-通讯》杂志发表了一项徐兵河院士领衔、来凯医药AKT抑制剂Afuresertib(LAE002)联合氟维司群治疗经治HR+/HER2-晚期乳腺癌1b期临床研究结果,该联合疗法在携带PIK3CA/AKT1/PTEN通路改变乳腺癌患者中展现出潜力的疗效、安全性结果。该刊文的发表,不仅展现了该临床研究在设计严谨性、过程透明度、结果质量等达到了国际水平;徐院士在论文结尾强调了研究验证了...
Source Link2月6日,《自然-通讯》杂志发表了一项徐兵河院士领衔、来凯医药AKT抑制剂Afuresertib(LAE002)联合氟维司群治疗经治HR+/HER2-晚期乳腺癌1b期临床研究结果,该联合疗法在携带PIK3CA/AKT1/PTEN通路改变乳腺癌患者中展现出潜力的疗效、安全性结果。该刊文的发表,不仅展现了该临床研究在设计严谨性、过程透明度、结果质量等达到了国际水平;徐院士在论文结尾强调了研究验证了...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.